Brynn E. Marks, MD, MSHPEd
Assistant Professor of Pediatrics (Endocrinology and Diabetes) at the Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
Division of Endocrinology and Diabetes
The Hub for Clinical Collaboration
3501 Civic Center Boulevard
7th Floor, Office 7547
Philadelphia, PA 19104
Division of Endocrinology and Diabetes
The Hub for Clinical Collaboration
3501 Civic Center Boulevard
7th Floor, Office 7547
Philadelphia, PA 19104
Office: 267-426-4925
Publications
Education:
BA (Psychology)
Georgetown University, 2007.
MD
Thomas Jefferson University Sidney Kimmel Medical College, 2011.
MSHPEd
Massachusetts General Hospital Institute of Health Professions, 2019.
BA (Psychology)
Georgetown University, 2007.
MD
Thomas Jefferson University Sidney Kimmel Medical College, 2011.
MSHPEd
Massachusetts General Hospital Institute of Health Professions, 2019.
Post-Graduate Training
Intern, Pediatrics, Jefferson Medical College/ Nemours AI duPont Hospital for Children, 2011-2012.
Resident, Pediatrics, Jefferson Medical College/ Nemours AI duPont Hospital for Children, 2012-2015.
Fellow, Pediatric Endocrinology, Boston Children’s Hospital, 2016-2019.
Permanent linkIntern, Pediatrics, Jefferson Medical College/ Nemours AI duPont Hospital for Children, 2011-2012.
Resident, Pediatrics, Jefferson Medical College/ Nemours AI duPont Hospital for Children, 2012-2015.
Fellow, Pediatric Endocrinology, Boston Children’s Hospital, 2016-2019.
Description of Clinical Expertise
type 1 diabetes, cystic fibrosis-related diabetes, post-transplant diabetesDescription of Research Expertise
type 1 diabetes, cystic fibrosis-related diabetes, diabetes technology, automated insulin delivery, continuous glucose monitor, insulin pump, medical education, healthcare inequitiesSelected Publications
Foster D, Allen M, Maxwell T, Xin R, Marks BE: Does Changing the Ketone Management Threshold Increase the Risk for DKA? A Quality Improvement Project International Society for Pediatric and Adolescent Diabetes 51st Conference, Montreal, Canada Nov 2025.Trelles AN, Gallop R, Rearson A, Marks BE : 90% Time in Automated Mode is Necessary but Not Sufficient to Attain Glycemic Targets with the Omnipod 5 International Society for Pediatric and Adolescent Diabetes 51st Conference, Montreal, Canada Nov 2025.
Meighan S, Clawges K, McCormick J, Marks BE: Priorities of Youth and Families in Choosing an Automated Insulin Delivery System International Society for Pediatric and Adolescent Diabetes 51st Conference, Montreal, Canada Nov 2025.
Vitale RJ, Ford C, Scully K, Marks B, Putman M: Sleep, body image, and mental health outcomes among people with and without cystic fibrosis-related diabetes in the yETI study. North American Cystic Fibrosis Conference, Seattle, WA Oct 2025.
Nally L, Sherr J, Garg S, Marks B, Laffel L, et al. : Safety and Glycemic Outcomes of the MiniMed™ 780G System with a Disposable All-in-One Sensor. Diabetes Technology & Therapeutics Aug 2025.
Nally LM, Sherr JL, Garg SK, Marks BE, Laffel LM, Pihoker C, Accacha SD, Thrasher JR, Abuzzahab MJ, Reed JH, Ekhlaspour L, Belapurkar S, Shulman DI, Sunil B, MacLeish SA, Latif K, Forlenza GP, Castorino K, Lal RA, Bode BW, Broyles FE, Carlson AL, Nwosu BU, Shin J, Ma H, Salbato A, Cordero TL, Treminio Y, McVean JJ, Rhinehart AS, Vigersky RA; SUCCEED Study Group. : Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor. Diabetes Technol Ther August 2025.
Lahoti A, Haque R, Bianco ME, Choudhary A, Clark AL, Marks BE, Pinnaro CT, Shah AS, Stefater-Richards M, Thaker VV, Wolf RM, Tryggestad JB: Trends of Diabetes in Youth (TrenDY) during COVID-19 across the United States. Journal of Clinical Endocrinology & Metabolism July 2025.
Gera S, Rearson A, Gallop RJ, Marks BE: Minimum Continuous Glucose Monitor Data Required to Assess Glycemic Control in Youth with Type 1 Diabetes. Diabetes Technology & Therapeutics July 2025.
Chu P, Parimi N, Wolf RM, Brown EA, Kelly A, Marks BE: Real-World Safety and Effectiveness of U200 Insulin Use in Automated Insulin Delivery Systems in Adolescents and Young Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics July 2025.
Wolf R, Patel D, Gera S, Molano G, DOliveira T, Meighan S, Brown E, Marks BE: Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control between White and Black Youth with Type 1 Diabetes? Diabetes Technology & Therapeutics June 2025.
Contact us
Institute for Diabetes, Obesity and Metabolism
Smilow Center for Translational Research
3400 Civic Center Boulevard, 12th Floor
Philadelphia, PA 19104
Phone: 215-898-0198 | Fax 215-898-5408
Directions
© Trustees of the University of Pennsylvania